PCOS Healthcare Trends · Evergreen explainer
Why PCOS is being renamed PMOS — and what it means for finding care
If you have searched for PCOS care lately, you may have met a second name: PMOS. In May 2026, a global consensus of experts formally renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome (PMOS). This piece explains why the old name was retired, what the new one is trying to say, and what the change means in practice when you are looking for a clinician.
The problem with the old name
Start with the word “cysts.” The “cysts” in polycystic ovary syndrome are not cysts at all — they are small follicles, the normal structures in an ovary that hold developing eggs. Many women with the condition do not even show that ultrasound picture. So the name pointed at a side detail, described it wrongly, and made a condition that involves hormones, metabolism, skin, hair, mood, and fertility sound like a problem with one organ.
The consensus authors put it plainly: the old name contributed to delayed diagnosis, fragmented care, and stigma. Women describe the pattern behind those words often — years of symptoms treated as separate problems by separate clinics, because nothing in the name told anyone to look at the whole picture.
How the decision was made
This was not a rebrand by a committee over a weekend. The process ran for roughly fourteen years, led by an international network of clinicians, researchers, and patient advocates coordinated from Monash University in Australia. Fifty-six professional and patient organizations took part. The final survey gathered responses from 14,360 people — 10,411 of them women living with the condition, and 3,949 health professionals. Large majorities of both groups supported changing the name: 85.6 percent of patients and 76.1 percent of professionals, as reported from the process.
The result was published in The Lancet on May 12, 2026, and the new name has been endorsed by the Endocrine Society, the American Society for Reproductive Medicine, and more than fifty other organizations. By the World Health Organization’s estimate, around 70 percent of women with the condition worldwide are undiagnosed — one reason the experts wanted a name that describes the condition accurately enough to be recognized sooner.
What the new name is saying
- Polyendocrine — many hormone systems are involved, not one. Androgens, insulin, and the signals between brain and ovary all play a part.
- Metabolic — blood sugar, insulin resistance, cholesterol, and long-term metabolic health are part of the condition itself, not side issues. They belong in the name because they belong in the care.
- Ovarian — the ovaries are still part of the picture: cycles, ovulation, and fertility. They are one part of three, not the whole story.
What did not change
- Your diagnosis. If you were diagnosed with PCOS, you have the same condition under its new name. Nothing about your case was re-judged.
- How diagnosis works. The diagnostic framework doctors use — generally two of three features: irregular ovulation, signs of androgen excess, and polycystic ovarian appearance, after ruling out look-alike conditions — is unchanged, as are the standards in the 2023 International Evidence-based Guideline.
- Your records, for now. Charts, insurance forms, referrals, and lab portals will keep saying PCOS for a while. That is expected, not an error.
- The timeline. Adoption is staged over roughly three years — guidelines, medical records systems, and education materials update in steps. Full use of PMOS alone is expected to land with the next international guideline, around 2028.
What this means when you are finding care
During a transition like this, the practical risk is a search problem: half the world’s pages, portals, and provider bios say PCOS, and a growing number say PMOS. If you search only one name, you will miss care described under the other. This directory indexes providers under both names for exactly that reason — the same listings, whichever term you type.
The rename is also a useful signal when you are reading a provider’s page. A clinician who uses PMOS, or who mentions both names, is showing they follow the current international consensus. It is one signal among several — it does not by itself say anything about the quality of anyone’s care — but it tells you their information is current.
And if the word “metabolic” in the new name is new information to you, that itself is worth a conversation at your next appointment: for many women, the metabolic half of this condition was never screened, because the old name never pointed at it.
Questions worth asking your provider
- Will my chart say PCOS or PMOS — and does the name used affect my referrals or coverage in any way I should know about?
- Which guideline do you follow for diagnosis and follow-up?
- Does my care include metabolic screening — blood sugar, cholesterol, blood pressure — or only cycle and fertility tracking?
- If I see different names in different portals, who keeps the full picture of my care in one place?
Sources
- Teede HJ, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet, May 2026 — read the consensus paper
- Plain-language coverage: News-Medical — why experts say PCOS needs a new name
- The guideline and consensus program’s home: Monash Centre for Health Research and Implementation
- Federal overview of the condition: NICHD — PCOS topic page
Looking for care? Find a PCOS/PMOS-focused provider or browse by state.
This article is general information published by the PMOS Directory. It is not medical advice and is not a substitute for professional medical advice, diagnosis, or treatment. It does not describe what any treatment does for any person, and it is not a recommendation for or against any treatment, product, or provider. Always seek the advice of your physician or other qualified health provider with any questions about a medical condition. If this is an emergency, call 911.